Pleomorphic (giant and spindle cell) carcinoma is genetically distinct from adenocarcinoma and squamous cell carcinoma by K-ras-2 and p53 analysis

American Journal of Clinical Pathology

Volumn 106, Issue 4, 1996, Pages 487-492

  Przygodzki, Ronald M ^a   Koss, Michael N ^a   Moran, Cesar A ^a   Langer, John C ^b   Swalsky, Patricia A ^c   Fishback, Nancy ^a   Bakker, Anke ^c   Finkelstein, Sydney D ^c  

^a ARMED FORCES INSTITUTE OF PATHOLOGY   (United States)

^b GEORGE WASHINGTON UNIVERSITY   (United States)

^c UNIVERSITY OF PITTSBURGH MEDICAL CENTER   (United States)

Author keywords

Giant cell carcinoma; Immunohistochemistry; K ras mutation; p53 mutation; Pleomorphic carcinoma; Spindle cell carcinoma; Topographic genotyping

Indexed keywords

DNA; PROTEIN P53;

ARTICLE; CONTROLLED STUDY; DNA SEQUENCE; GENOTYPE; GIANT CELL CARCINOMA; HUMAN; HUMAN TISSUE; LUNG ADENOCARCINOMA; LUNG CARCINOMA; MUTATION; ONCOGENE K RAS; PLEOMORPHIC ADENOMA; PRIORITY JOURNAL; SPINDLE CELL CARCINOMA; SQUAMOUS CELL CARCINOMA;

EID: 0029784406     PISSN: 00029173     EISSN: None     Source Type: Journal    
DOI: 10.1093/ajcp/106.4.487     Document Type: Article

References (27)

1. The World Health Organization histological typing of lung tumors. Am J Clin Pathol 1982;77:123-36.
2. Fishback NF, Travis WD, Moran CS, et al. Pleomorphic (spindle/ giant cell) carcinoma of the lung. Cancer 1994;73(12):2936-45.
3. Colby TV, Koss MN, Travis WD. Tumors of the lower respiratory tract. In: Rosal J, ed. Atlas of Tumor Pathology. ed 3, vol 13. Washington, DC: Armed Forces Institute of Pathology, 1995.
4. Hsu SM, Raine L, Fanger H. The use of antiavidin antibody and avidin-biotin-peroxidase complex in immunoperoxidase technics. Am J Clin Pathol 1981;75:816-821.
5. Finkelstein SD, Sayegh R, Christensen S, Swalsky PA. Genotypic classification of colorectal adenocarcinoma: Biologic behavior correlates with K-ras-2 mutation type. Cancer 1993;71:3827-3838.
6. Finkelstein SD, Sayegh R, Bakker A, Swalsky PA. Determination of tumor aggressiveness in colorectal cancer by K-ras-2 analysis. Arch Surg 1993;128:526-531.
7. Rodenhuls S, Slebos RJ. Clinical significance of ras oncogene activation in human lung cancer. Cancer Res 1992;52(Suppl 9): 2665S-2669S.
8. Rodenhuis S, Slebos RJ. The ras oncogenes in human lung cancer. Am Rev Respir Dis 1990;142:S27-S30.
9. Suglo K, Ishida T, Yokoyama H, et al. ras gene mutations as a prognostic marker in adenocarcinoma of the human lung without lymph node metastasis. Cancer Res 1992;52:2903-2906.
10. Rosell R, Li S, Skacel Z, et al. Prognostic impact of mutated K-ras gene in surgically resected non-small cell lung cancer patients. Oncogene 1993;8:2407-2412.
11. Finkelstein SD, Przygodzki R, Bakker A, Swalsky PA. K-ras-2 genotyping of colorectal, lung, and pancreatic adenocarcinoma (Abstr). Proc Annu Meet Am Assoc Cancer Res 1994;35:A1326.
12. Slebos RJ, Hruban RH, Dalesio O, et al. Relationship between K-ras oncogene activation and smoking in adenocarcinoma of the human lung. J Natl Cancer Inst 1991;83:1024-1027.
13. Westra WH, Slebos RJ, Offerhaus GJ, et al. K-ras oncogene activation in lung adenocarcinomas from former smokers: Evidence that K-ras mutations are an early and irreversible event in the development of adenocarcinoma of the lung. Cancer 1993;72:432-438.
14. Sarkar FH, Valdivieso M, Raval M, et al. Evaluation of K-ras and p53 gene mutation in non-small cell lung cancer by polymerase chain reaction (PCR) (Abstr). Proc Annu Meet Am Soc Clin Oncol 1994;13:A308.
15. Li ZH, Zheng J, Weiss LM, Shibata D. c-K-ras and p53 mutations occur very early in adenocarcinoma of the lung. Am J Pathol 1994;144:303-309.
16. Bennett WP, Colby TV, Travis WD, et al. p53 protein accumulates frequently in early bronchial neoplasia. Cancer Res 1993;53: 4817-4822.
17. Nuorva K, Soini Y, Kamel D, et al. Concurrent p53 expression in bronchial dysplasias and squamous cell lung carcinomas. Am J Pathol 1993;142:725-732.
18. Papadakis E, Linardopoulos S, Malliri A, et al. Expression of ras and p53 proteins in surgically treated human lung adenocarcinomas and squamous cell lung carcinomas (Abstr). Proceedings of the Eighth Mediterranean Congress of Chemotherapy, Athens, Greece, May 24-29, 1992:661.
19. Sozzi G, Miozzo M, Donghi R, et al. Deletions of 17p and p53 mutations in preneoplastic lesions of the lung. Cancer Res 1992;52:6079-6082.
20. Zheng J, Shu Q, Li ZH, et al. Patterns of p53 mutations in squamous cell carcinoma of the lung: Acquisition at a relatively early age. Am J Pathol 1994;145:1444-1449.
21. Hollstein M, Sidransky D, Vogelstein B, Harris CC. p53 mutations in human cancers. Science 1991;253:49-53.
22. Rodenhuis S, Top B, Klaver SG, et al. Oncogenes and response prediction in human tumors. Annu Rep Neth Cancer Inst 1993;1993:78.
23. Przygodzki RM, Finkelstein SD, Langer JC, et al. Analysis of p53, K-ras-2 and C-raf-1 in pulmonary neuroendocrine tumors:Correlation with histologic subtype and clinical outcome. Am J Pathol 1996;148:1531-1541.
24. Lane DP. p53 and human cancers. Br Med Bull 1994;50:582-599.
25. Lane DP. p53, guardian of the genome. Nature 1992;58:15-16.
26. Harris CC, Bennett WP, Hollstein MC. p53 tumor suppressor gene involvement in human carcinogenesis (Abstr). Sixth p53 Workshop, Tiberias, Israel, November 1-5, 1992:1.
27. Ryberg D, Kure E, Lystad S, et al. p53 mutations in lung tumors: Relationship to putative susceptibility markers for cancer. Cancer Res 1994;54:1551-1555.